Merck & Co., Inc. (MRK) Depreciation & Amortization
The d&a for Merck & Co., Inc. (MRK) is $5.84 Billion with a year-over-year change of +29.76%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
MRK D&A Chart
Current D&A
$5.84B
$5.84 Billion
Year-over-Year Change
+29.76%
vs. $4.50B prior year
Historical Data
30
Years of data available
Annual D&A History
| Year | D&A | YoY Change | % Change |
|---|---|---|---|
| 2025 | $5.84B | +$1.34B | +29.76% |
| 2024 | $4.50B | +$627.00M | +16.19% |
| 2023 | $3.87B | $-37.00M | -0.95% |
| 2022 | $3.91B | +$695.00M | +21.62% |
| 2021 | $3.21B | $-272.00M | -7.80% |
| 2020 | $3.49B | +$176.00M | +5.32% |
| 2019 | $3.31B | $-1.21B | -26.75% |
| 2018 | $4.52B | $-157.00M | -3.36% |
| 2017 | $4.68B | $-795.00M | -14.53% |
| 2016 | $5.47B | $-904.00M | -14.18% |
| 2015 | $6.38B | $-316.00M | -4.72% |
| 2014 | $6.69B | $-297.00M | -4.25% |
| 2013 | $6.99B | +$10.00M | +0.14% |
| 2012 | $6.98B | $-449.00M | -6.05% |
| 2011 | $7.43B | +$46.00M | +0.62% |
| 2010 | $7.38B | +$4.80B | +186.53% |
| 2009 | $2.58B | +$945.00M | +57.94% |
| 2008 | $1.63B | $-357.20M | -17.97% |
| 2007 | $1.99B | $-280.20M | -12.35% |
| 2006 | $2.27B | +$560.30M | +32.80% |
| 2005 | $1.71B | +$257.40M | +17.74% |
| 2004 | $1.45B | +$136.50M | +10.39% |
| 2003 | $1.31B | +$83.00M | +6.74% |
| 2002 | $1.23B | +$98.70M | +8.72% |
| 2001 | $1.13B | $-144.80M | -11.34% |
| 2000 | $1.28B | $-184.90M | -12.65% |
| 1999 | $1.46B | +$447.10M | +44.04% |
| 1998 | $1.02B | +$178.00M | +21.26% |
| 1997 | $837.10M | $-90.00M | -9.71% |
| 1996 | $927.10M | — | — |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis